Publications by authors named "Pilar Lopez-Juarez"
Article Synopsis
- SARS-CoV-2 infection leads to a wide range of symptoms, with most individuals experiencing mild to moderate cases while a minority develop severe illness requiring intensive care.
- Researchers have focused on identifying biomarkers linked to the severity of the disease and long-COVID, but little is known about the persistence of these biomarkers years after recovery.
- A study found that even two years after infection, specific biomarkers related to severe COVID-19 were still present in asymptomatic patients, indicating lasting changes in the nasopharyngeal area and suggesting a connection between biomarker presence and the severity of prior infection.
The Sequential Organ Failure Assessment (SOFA) could function as an effective risk stratification tool in the admission of critically ill patients with COVID-19 and would allow stratification based on a risk assessment. We aimed to examine whether the SOFA score is useful to define 2 severity profiles in COVID-19 patients admitted to ICU: mild with SOFA < 5, and severe with SOFA ≥ 5. A retrospective cohort, multicenter study was conducted from February 11 to May 11, 2020.
View Article and Find Full Text PDFAprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.
Eur J Clin Invest
June 2022
Background: SARS-CoV-2 virus requires host proteases to cleave its spike protein to bind to its ACE2 target through a two-step furin-mediated entry mechanism. Aprotinin is a broad-spectrum protease inhibitor that has been employed as antiviral drug for other human respiratory viruses. Also, it has important anti-inflammatory properties for inhibiting the innate immunity contact system.
View Article and Find Full Text PDFIntroduction: Spain is one of the countries with the highest number of COVID-19 patients. Unfortunately, few data for regions are available.
Objectives: This study aimed to describe the characteristics and independent risk factors associated with COVID-19 mortality in Castilla-La Mancha, Spain.